2024 success fuels revenue and earnings growth
Allerød, 28th April 2025
A strategic focus on product innovation and market expansion secures Qufora a strong result in 2024, with a 22% increase in revenue and an EBITDA margin of 25.8%.
The Danish medtech company Qufora is a significant international player in the market for innovative aids in gastroenterology and urology. Headquartered in Allerød, Denmark, the company is represented in multiple European markets and has received international recognition for its award-winning designs.
With a 22% revenue increase to DKK 243.2 million and a 23% EBITDA growth to DKK 62.7 million — equal to a margin of 25.8% — Qufora maintained strong growth in 2024. During the same period, the company expanded from 80 to 102 employees and now operates five subsidiaries in the United Kingdom, Germany, Italy, the Netherlands, and Sweden.
Our growth strategy is based on our ability to attract talented colleagues and develop innovative products that enable individuals with chronic bowel conditions to live a better life. Therefore, it is also crucial for us to maintain an inspiring and creative work environment — with openness, efficient decision-making processes, and a strong customer focus.
Valuable Research and Product Innovation
Bowel irrigation as a treatment method has been known for centuries, but in terms of medical devices and clinical research, it is still in its early stages. Qufora is committed to leading the industry by supporting important research that can contribute new knowledge and strengthen clinical practice. To this end, Qufora has established a Medical Affairs team and invested in a broad range of clinical trials. These initiatives will provide healthcare professionals with better insights into how treatment strategies work and create opportunities to introduce bowel irrigation earlier during patient care.
Qufora’s mission to develop clinical solutions for patients with chronic bowel disorders was further realised in 2024 with the launch of new enhancements in the popular MiniGo and MiniGo Flex portfolios — including a unique variant specifically designed for children, a vulnerable group that is a top priority for the company to support.
New Investor and Further Growth
On 1st September 2024, leading Nordic healthcare investor Impilo became Qufora’s majority shareholder. This partnership positions Qufora strongly to continue its growth strategy and develop groundbreaking products that improve patients’ lives.
For nearly 20 years, Qufora has grown in a healthy and solid way, rooted in the company’s strong values, strategy, and culture. The passion and professionalism can be felt throughout the organisation, and the owners are very pleased with Qufora’s development, which once again has exceeded expectations.
Photo: CEO Lena Ehmsen Lachenmeier and Chairman of the Board Mikael Worning
Learn more
Working at Qufora
As a company, we put emphasis on being an attractive workplace, with room for inclusiveness, creativity and openness.
Who we are
Qufora is a medical device company that works to enable people with chronic bowel disorders to live a better life.
Annual reports
Our annual reports highlight our work in bowel care, sharing progress, insights and our ongoing commitment to improving the lives of people with chronic bowel disorders.